0VZ7 Stock Overview
Operates in the pharmaceutical sector in Germany. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
+ 1 more risk
HAEMATO AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.99 |
| 52 Week High | €28.00 |
| 52 Week Low | €14.99 |
| Beta | 1.29 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 33 Year Change | -43.87% |
| 5 Year Change | n/a |
| Change since IPO | -73.24% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0VZ7 | GB Healthcare | GB Market | |
|---|---|---|---|
| 7D | 0% | -3.1% | -1.7% |
| 1Y | n/a | -23.4% | 5.1% |
Return vs Industry: Insufficient data to determine how 0VZ7 performed against the UK Healthcare industry.
Return vs Market: Insufficient data to determine how 0VZ7 performed against the UK Market.
Price Volatility
| 0VZ7 volatility | |
|---|---|
| 0VZ7 Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 6.4% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.0% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0VZ7 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 0VZ7's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1993 | 76 | Patrick Brenske | www.haemato.ag |
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. It operates through Specialty Pharma and Lifestyle & Aesthetics segments. The company engages in the development, acquisition, licensing, and distribution of prescription drugs and OTC products, special cosmetics, as well as dietary supplements.
HAEMATO AG Fundamentals Summary
| 0VZ7 fundamental statistics | |
|---|---|
| Market cap | €87.82m |
| Earnings (TTM) | €9.61m |
| Revenue (TTM) | €260.81m |
9.1x
P/E Ratio0.3x
P/S RatioIs 0VZ7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0VZ7 income statement (TTM) | |
|---|---|
| Revenue | €260.81m |
| Cost of Revenue | €241.08m |
| Gross Profit | €19.73m |
| Other Expenses | €10.12m |
| Earnings | €9.61m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.84 |
| Gross Margin | 7.56% |
| Net Profit Margin | 3.68% |
| Debt/Equity Ratio | 0.2% |
How did 0VZ7 perform over the long term?
See historical performance and comparison